What is Leerink Partnrs’ Estimate for RARE FY2025 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued on Tuesday, November 4th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will post earnings per share of ($6.13) for the year, down from their prior estimate of ($5.20). The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($1.58) EPS, Q1 2026 earnings at ($1.75) EPS, Q2 2026 earnings at ($1.58) EPS, Q3 2026 earnings at ($1.67) EPS, Q4 2026 earnings at ($1.42) EPS, FY2026 earnings at ($6.41) EPS and FY2027 earnings at ($1.42) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. During the same quarter last year, the company earned ($1.40) EPS. The firm’s revenue for the quarter was up 14.6% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS.

Other analysts have also issued research reports about the stock. Wedbush lowered their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Canaccord Genuity Group decreased their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Morgan Stanley reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, July 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $82.75.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $30.63 on Friday. The company has a market capitalization of $2.95 billion, a P/E ratio of -5.54 and a beta of 0.30. The company’s 50-day moving average is $31.47 and its 200 day moving average is $32.85. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $53.04.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Ultragenyx Pharmaceutical by 28.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company’s stock worth $116,559,000 after buying an additional 706,519 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Ultragenyx Pharmaceutical by 81.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock valued at $77,815,000 after acquiring an additional 965,919 shares in the last quarter. Federated Hermes Inc. increased its holdings in Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company’s stock worth $74,419,000 after acquiring an additional 5,400 shares during the period. Geode Capital Management LLC lifted its stake in Ultragenyx Pharmaceutical by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company’s stock worth $62,291,000 after purchasing an additional 66,394 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in Ultragenyx Pharmaceutical by 0.5% in the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after purchasing an additional 8,385 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 7,942 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the sale, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 10,456 shares of company stock worth $328,486 in the last three months. Insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.